In afatinib-resistant non-small cell lung cancer cells, overexpression of FGFR1 and FGF2 played a role in overcoming cell survival by compensating the loss of the estrogen growth factor receptor (EGFR)-driven signalling pathway [198]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.